Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan)
https://doi.org/10.17650/1994-4098-2011-0-1-113-118
Abstract
The efficacy and safety of intravenous topotecan (hycamtin) given in a dose of 4 mg/m2 on days of 1, 8, 15 of a 28-day cycle of its therapy were evaluated in patients with recurrent ovarian cancer (OC).
Preliminary analysis of the safety and toxicity of the topotecan regimen demonstrated no impact on quality of life, easiness-to-use, and possible outpatient use. Topotecan showed to be effective as second- and higher line therapy for recurrent OC to carry out a platinum reduction.
About the Authors
E. G. Novikova
Department of Gynecology, P.A. Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of the Russian Federation
Russian Federation
Russian Federation
I. A. Korneyeva
Department of Gynecology, P.A. Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of the Russian Federation
Russian Federation
Russian Federation
E. Yu. Moskovskaya
Department of Gynecology, P.A. Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of the Russian Federation
Russian Federation
Russian Federation
References
1. Злокачественные новообразования в России в 2008 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.: ФГУ МНИОИ им. П.А. Герцена Росмедтехнологий, 2010; с. 130–1.
2. Hennessy B.T., Coleman R.L., Markman M. Ovarian cancer. Lancet 2009;374:1371–82.
3. Safra T., Menczer J., Bernstein R., Shpigel S. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 2007;105:205–10.
4. Ozols R.F., Rubin S.C., Thomas G. Epithelial ovarian cancer. In: Principles and practice of gynecologic oncology. Hoskins W.J., Perez C.A., Young R.C. eds. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005; p. 919–22.
5. Pujade-Lauraine E., Paraiso D., Cure H. Predicting the effectiveness of chemotherapy (CX) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc Am Soc Clin Oncol 2002;21:abstr 829.
6. Marcman M., Marcman J., Webster K. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22:3120–5.
7. Hertzberg R.P., Caranfa M.J., Hecht S.M. On mechanism of topoisomerase I ingibition by camptotecine: evidence for binding to an enzyme-DNA complex. Biochemistry 1989;28:4629–38.
8. Clements M.K., Jones C.B., Cumming M., Daoud S.S. Antiangiogenic potencial of camptotecine and topotecan. Cancer Chemother Pharmacol 1999;44:411–6.
9. Gordon A.N., Fleagle J.T., Guthrie D. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegilated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312–22.
10. Marcman M., Hall J. Phase II trial of weekly single-agent paclitaxel in platinum paclitaxel-refractory ovarian cancer. J Clin Oncol 2002:20:2365–9.
11. Bence A., Mattingly C. Evaluation of topotecan cytotoxicity and topoisomerase I levels in non-small cell lung cancer cells. Proc Am Assoc Cancer Res 2002;43:247; abstr 1227.
12. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2006. CA Cancer J Clin 2006:56:106–30.
13. Bristow R.E., Tomacruz R.S., Armstrong D.K. et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248–59.
14. Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989;59:1989.
Review
For citations:
Novikova E.G., Korneyeva I.A., Moskovskaya E.Yu. Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan). Tumors of female reproductive system. 2011;(1):113-118. (In Russ.) https://doi.org/10.17650/1994-4098-2011-0-1-113-118
Views:
499
Email this article 